Campath Development in CLL
Phase I/II Dose Ranging Studies (001, 002, 003) 30 mg 3x/week selected for Phase II studies
Phase II Studies (125-005, 125-009) 30 mg 3x/week
Pivotal study (CAM211) initiated April
End of Phase II meetings with the FDA
Millennium and ILEX Partners, LP